Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cocrystal Pharma, Inc. (COCP) on August 12, 2026. The company is incorporated in Delaware and trades on The Nasdaq Capital Market. The report addresses corporate governance changes effective immediately as of the filing date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a board appointment and does not contain financial statements or performance data.
Material Changes
The primary material change disclosed is the appointment of Carol L. Brosgart as a director of the Company by the Board of Directors, effective August 12, 2026. The filing confirms there are no related party transactions involving Ms. Brosgart requiring disclosure under Item 404(a) of Regulation S-K, nor are there family relationships between her and existing directors or officers.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. No forward-looking statements regarding financial performance or operational strategy are included in this specific report.
Investor Verification Checklist
- Verify the professional background and qualifications of the newly appointed director, Carol L. Brosgart.
- Confirm the total number of directors on the Board following this appointment.
- Review the company's most recent 10-Q or 10-K filing for current financial metrics, as this 8-K does not contain them.